Sign In
Buy MNK
$0.116
+0 (+0%)
At Close: Jul 20, 2022
Drugmakers Mallinckrodt, Endo to Merge, Plan NYSE Listing
12:51pm, Thursday, 13'th Mar 2025
Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange (NYSE), the two drugmakers said Thursday.
Mallinckrodt, Endo Merger to Create Diversified Pharmaceuticals Firm
07:40am, Thursday, 13'th Mar 2025
Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint.
Mallinckrodt plc (in examinership) Receives U.S. Court Approval for Financial Restructuring Plan
01:49pm, Tuesday, 10'th Oct 2023
DUBLIN , Oct. 10, 2023 /PRNewswire/ -- Mallinckrodt plc (in examinership) (OTCMKTS: MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that its Plan o
– Clinical findings from historical manuscript published in Clinical Drug Investigation reinforce the efficacy, safety profile, and use of Acthar Gel in appropriate patients across 12 autoimmune a
NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), the New York City-based investment advisor to certain clients with financia
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 5, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of inves
Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse
03:49pm, Thursday, 31'st Aug 2023
Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.
DUBLIN , Aug. 31, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that its Specialty Generics segment, operating as SpecGx LLC, rece
MNK Investors Have Opportunity to Lead Mallinckrodt plc Securities Fraud Lawsuit
12:36pm, Wednesday, 30'th Aug 2023
LOS ANGELES , Aug. 30, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit agains
Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing Operations
11:54am, Wednesday, 30'th Aug 2023
Continuing to Serve Customers and Deliver High-Quality Therapies to Patients Without Interruption; Vendors and Suppliers to be Paid in Full in the Ordinary Course DUBLIN , Aug. 30, 2023 /PRNewswire/ -
NYSE American to Commence Delisting Proceedings Against Mallinckrodt plc (MNK)
04:15pm, Monday, 28'th Aug 2023
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the Ordinary
NEW YORK , Aug. 28, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK), and certain officer
Mallinckrodt discloses grand jury subpoena, makes bankruptcy filing official
11:10am, Monday, 28'th Aug 2023
Mallinckrodt PLC made it official Monday, with the Dublin, Ireland-based drugmaker filing for bankruptcy for the second time in three years after struggling to make settlement payments for its role in
Drugmaker Mallinckrodt files for second bankruptcy in the US
01:19am, Monday, 28'th Aug 2023
Drugmaker Mallinckrodt on Monday said the company and some of its units have filed for a second bankruptcy in 3 years in the U.S., with the newest restructuring plan set to reduce its debt by about $1
Initiates Voluntary Prepackaged Chapter 11 Proceedings with Overwhelming Support of Key Stakeholders, Including 85%+ of First and Second Lien Debtholders Continuing to Operate Normally, Serve Customer
